Pharmaceutical

Neuvivo makes bid to enter ALS arena with immunotherapy candidate

NP001 is designed to tackle the neurodegenerative disease through an immunologic mechanism as opposed to a neurologic one.

Oct 8, 2024 - 04:00
Neuvivo makes bid to enter ALS arena with immunotherapy candidate
NP001 is designed to tackle the neurodegenerative disease through an immunologic mechanism as opposed to a neurologic one.
Read the original article

Tags:

Previous Article

A rational design approach to RNA targeting could replace large-scale screening

Next Article

EMA starts review into hair loss drugs about potential link to suicidal thoughts 

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA official pushes for a dedicated emerging pathogens team to prepare for the next pandemic

STAT+: FDA official pushes for a dedicated emerging pat...

Jul 22, 2023

Tagrisso plus chemo has FDA priority review for metastatic EGFRm NSCLC

Tagrisso plus chemo has FDA priority review for metasta...

Oct 17, 2023

ChatGPT doesn’t know much about drugs, Hims & Hers enters weight-loss market

ChatGPT doesn’t know much about drugs, Hims & Hers ente...

Dec 5, 2023